Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Our strategy is based on an integrated business model that has allowed us to build a portfolio of differentiated clinical and pre-clinical assets as well as a robust commercial portfolio.
Upcoming Events
February 18, 2025
FY 2024 Revenues and Cash
March 20, 2025
FY 2024 Financial Results
Jefferies 2024 Global Healthcare Conference
Valneva presented at the Jefferies London Healthcare Conference.
Access the webcast of a fireside chat with our CEO here.
Contact
Investor Relations Team
Campus Bio-Ouest6, Rue Alain Bombard
44800 Saint-Herblain, France T: +33 2 28 07 37 10 investors@valneva.com